Lipitor Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Lipitor Diabetes Litigation

The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statins.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
Our Firm has heard from numerous individuals who allegedly developed Type 2 diabetes due to their use of Lipitor. We are pleased to see the federal Lipitor diabetes claims moving forward, and look forward to significant progress in the coming months.

New York, New York (PRWEB) March 25, 2014

Hundreds of Lipitor lawsuits (http://www.thelipitorlawsuit.com/) that allege use of the statin drug caused patients to develop new-onset Type 2 diabetes have begun to move forward in a multidistrict litigation underway in U.S. District Court, District of South Carolina. According to an Order dated February 26, 2014, the proceeding’s first status conference will be convened on Thursday, March 27th, before U.S. District Judge Richard K. Gergel. At that time, the Court will address a number of issues, including the appointment of plaintiffs’ attorneys to various leadership positions in the litigation, as well as procedures for the service of documents, the scheduling of regular status conferences, a discovery schedule, and the status of any Lipitor diabetes claims pending in state courts. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“Our Firm has heard from numerous individuals who allegedly developed Type 2 diabetes due to their use of Lipitor. We are pleased to see the federal Lipitor diabetes claims moving forward, and look forward to significant progress in the coming months,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The firm is currently offering free Lipitor lawsuit consultations to anyone who may have been harmed by this medication.

Lipitor Diabetes Allegations
According to court documents, all of the Lipitor lawsuits pending in the District of South Carolina allege that use of the statin drug caused previously healthy women to develop new-onset Type 2 diabetes. Among other things, the lawsuits claim that Pfizer Inc. knew of the association between Lipitor and diabetes, but concealed this information in order to protect sales of the medication. Plaintiffs further allege that had Pfizer provided doctors and the public with adequate warnings about the risk of diabetes, they would have chosen not to use the medication, or could have diligently monitored their blood glucose levels in order to avoid developing the disease.

The Lipitor diabetes litigation was established in the District of South Carolina on February 18, 2014, when 56 claims were transferred to the jurisdiction by the U.S. Judicial Panel on Multidistrict Litigation. According to an updated docket report issued by the Panel on March 13, 2014, at least 270 Lipitor lawsuits are now pending in the proceeding.

According to court documents, Lipitor lawsuits began mounting in courts around the country after the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statins to add new information to their product labels regarding a possible increased risk of Type 2 diabetes. The agency acted after a study published in JAMA: Internal Medicine in January 2012 reported that post-menopausal women treated with drugs like Lipitor were at increased risk of developing new-onset Type 2 diabetes. * However, plaintiffs in Lipitor lawsuits claim that the warnings added to the drug’s label by Pfizer following the FDA’s 2012 mandate remain inadequate.

Lipitor patients who allegedly developed Type 2 diabetes while using this medication may be entitled to compensation from Pfizer, Inc. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thelipitorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author